Logo

Incyte's Jakafi (ruxolitinib) Receives the US FDA's Approval for the Treatment of Chronic Graft-Versus-Host Disease

Share this

Incyte's Jakafi (ruxolitinib) Receives the US FDA's Approval for the Treatment of Chronic Graft-Versus-Host Disease

Shots:

  • The approval is based on the P-III REACH3 study evaluates the safety & efficacy of Jakafi vs BAT in patients ≥12yrs. with steroid-refractory chronic GVHD after the failure of 1 or 2 lines of systemic therapy
  • The results showed that the patients treated with Jakafi led to significantly improved outcomes across a range of efficacy measures- ORR (49.7% vs 25.6%) @24wks. Additionally- ORR (70% vs 57%) through Cycle 7 Day 1. The results were published in the NEJM
  • Jakafi is a JAK1/JAK2 inhibitor & marks 4th FDA-approved indication. Patients treated with Jakafi have access to the IncyteCARES program that offers patient support- including financial assistance- education & resources

Click here  | Ref: Businesswire | Image: List 23

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions